Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Fineline Cube Mar 2, 2026
Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Fineline Cube Mar 2, 2026
Company Drug

Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...

Company Drug

Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer

Fineline Cube Apr 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Pipeline with NMPA Approvals for Three Drugs

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National...

Company Deals

Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development

Fineline Cube Apr 10, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has...

Company Deals

Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline

Fineline Cube Apr 10, 2024

Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the...

Company Deals

Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China

Fineline Cube Apr 10, 2024

US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for HRS-4642 Clinical Trial in KRAS G12D Mutated Tumors

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

Alphamab Oncology’s JSKN003 Demonstrates Promising Results in Phase I HER2-Targeted Solid Tumor Study

Fineline Cube Apr 10, 2024

Alphamab Oncology (HKG: 9966) presented compelling data from a Phase I clinical trial of its...

Company Drug

Gan & Lee Pharmaceuticals Commences Clinical Trial for Innovative GLP-1 Agonist GZR18

Fineline Cube Apr 9, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading Chinese pharmaceutical company, has announced the commencement...

Company

BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle

Fineline Cube Apr 9, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has announced the operational...

Drug R&D

Shanghai’s 9th People’s Hospital Launches Groundbreaking Gene Therapy Trial for Congenital Deafness

Fineline Cube Apr 9, 2024

In a medical first, Shanghai’s 9th People’s Hospital has initiated the world’s inaugural clinical trial...

Policy / Regulatory

Shanghai Health Commission Implements Strict Guidelines to Curb Medical Sector Misconduct

Fineline Cube Apr 9, 2024

The Shanghai Municipal Health Commission has issued the “Implementation Rules for the Nine Guidelines for...

Company Drug

GSK’s ViiV Healthcare Expands Dovato Indication to Include Adolescents with HIV-1 Infection

Fineline Cube Apr 9, 2024

GlaxoSmithKline’s (GSK; NYSE: GSK) ViiV Healthcare has received an indication extension from the US Food...

Company Drug

Johnson & Johnson’s Xarelto Demonstrates Reduced Bleeding Risk in Atrial Fibrillation Patients Post-PCI

Fineline Cube Apr 9, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from a Phase...

Company Drug

Clover Bio’s SCB-1019 Vaccine Candidate Shows Promising Results in Phase I Trial

Fineline Cube Apr 9, 2024

Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary...

Company Drug

Bristol Myers Squibb Reports Positive Long-Term Data for KarXT in Schizophrenia Trial

Fineline Cube Apr 9, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced preliminary long-term data from a...

Company Drug

Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202

Fineline Cube Apr 9, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from...

Company Deals Drug Medical Device

Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab

Fineline Cube Apr 9, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...

Company Drug

CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing

Fineline Cube Apr 9, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...

Company Deals

Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies

Fineline Cube Apr 9, 2024

UK life sciences investment firm Medicxi has taken the lead in a $62 million Series...

Posts pagination

1 … 339 340 341 … 628

Recent updates

  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
  • Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis
  • Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma
  • Hangyu Pharma’s Sosimerasib Wins NMPA Approval – First KRAS G12C Inhibitor for Post‑Therapy NSCLC in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Company Drug

Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis

Company Drug

Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.